Repository logo

Browsing by Person "Asemi, Zatollah"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    A meta-analysis of cumin (Cuminum cyminim L.) consumption on metabolic and anthropometric indices in overweight and type 2 diabetics
    (Elsevier, 2018-03-23) Jafarnejad, Sadegh; Tsang, Catherine; Taghizadeh, Mohsen; Asemi, Zatollah; Keshavarz, Seyed Ali
    Objective To conduct a systematic review, including meta-analysis, of published randomised controlled trials (RCTs) of cumin to determine the effect on anthropometric and metabolic indices in overweight and/or type 2 diabetics, relative to controls. Methods Studies were identified by a search of electronic databases before December 2017. Combined and stratified analyses were used. Results Seven trials were identified, and data from 412 subjects were included. Pooled analysis showed improvements in bodyweight, body mass index (BMI) and fasting blood glucose (FBG) by −1.74 kg, −0.67 kg/m2 and −17.82 mg/dL respectively. Significant findings were also observed in triglycerides (TG) [WMD: −21.23 (95% CI: −37.64 to −4.82; P < 0.001, I2 = 92%)] and HDL-c (high-density lipoprotein cholesterol) [WMD: 4.16 (95%CI: 3.30, 5.01; P < 0.001, I2 = 82%)] following cumin intake. No changes were found in controls. Conclusions Cumin improves anthropometric and metabolic indices in overweight and/or type 2 diabetic subjects. The changes were related to the clinical condition and quality assessment.
  • No Thumbnail Available
    Item
    A meta-analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity
    (Wiley, 2019-05-21) Tsang, Catherine; Taghizadeh, Mohsen; Aghabagheri, Elahe; Asemi, Zatollah; Jafarnejad, Sadegh
    The role of chromium as a weight loss agent remains questionable, and although previous meta-analyses findings have reported small reductions in body weight in individuals with overweight/obesity following chromium supplementation, there have been significant limitations with these findings. The objective of this meta-analysis was to evaluate the current evidence for the efficacy of oral chromium supplementation in individuals with overweight/obesity from randomized controlled trials. Studies were identified by a search of electronic databases from inception to November 2018 and combined and stratified analyses were used. Twenty-one trials from 19 studies were identified which met all inclusion criteria which were suitable for statistical pooling, and data from 1316 participants were included. Pooled analysis showed significant reductions in anthropometric indices associated with body composition; for weight loss (weighted mean difference [WMD]: −0.75 kg, 95% confidence interval [CI], −1.04, −0.45, P < 0.001), body mass index (WMD: −0.40, 95% CI, −0.66, −0.13, P = 0.003 and body fat percentage (WMD: −0.68%, 95% CI, −1.32, −0.03, P = 0.04) in individuals with overweight/obesity. No changes were detected in controls. Subgroup analysis showed significant improvements in weight loss and body fat percentage, particularly for study durations ≤12 weeks and doses ≤400 μg/d. Chromium supplementation was associated with some improvements in body composition in subjects with obesity/overweight. The effect size was medium and the clinical relevance of chromium as a weight loss aid remains uncertain. Further investigation from larger and well-designed randomized controlled studies, especially in patients with diabetes, is warranted.